[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ais\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ais":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,67,96,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100638388","phase-1-a-phase-i-trial-of-umbilical-cord-mesenchymal-stromal-cells-for-acute-ischemic-stroke-100638388",false,"NCT07628933","A Phase I Trial of Umbilical Cord Mesenchymal Stromal Cells for Acute Ischemic Stroke","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Human Umbilical Cord-derived Mesenchymal Stromal Cell Injection in Patients With Acute Ischemic Stroke (AIS)","Inclusion Criteria:\n\n* Age ≥18 years, both genders included.\n* Clinical diagnosis of anterior circulation ischemic stroke, and able to receive the investigational product within 48 hours after the onset of stroke symptoms.\n* National Institutes of Health Stroke Scale (NIHSS) score of 6-20 (inclusive), with a score of \\\u003C2 on item Ia of the NIHSS.\n* Pre-stroke modified Rankin Scale (mRS) score ≤1.\n* The participant voluntarily agrees to participate in this study, signs the informed consent form personally or via a legal guardian, and has good compliance.\n\nExclusion Criteria:\n\n* Planned or already performed thrombectomy for the current stroke.\n* Treatment with neuroprotective agents after the current stroke.\n* History of cerebral hemorrhage, subarachnoid hemorrhage, or hemorrhagic transformation after the current ischemic stroke, and judged by the investigator to be unsuitable for participation in the clinical trial.\n* Uncontrolled systemic diseases, including but not limited to: hypertension (systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure ≥100 mmHg), diabetes mellitus (acute diabetic complications such as ketoacidosis, hyperglycemic hyperosmolar state, lactic acidosis, or hypoglycemic coma within the past 3 months, or glycated hemoglobin \\>8.5%, or poorly controlled blood glucose \\[blood glucose \\>16.8 mmol\u002FL or \\\u003C2.8 mmol\u002FL\\]), renal disease (eGFR \\\u003C30 mL\u002Fmin), liver failure (Child-Pugh Class C), severe heart failure (New York Heart Association \\[NYHA\\] Class IV), severe chronic respiratory disease.\n* Organ function meeting any one or more of the following criteria:\n\n  1. Absolute neutrophil count (ANC) \\\u003C1.5×10⁹\u002FL, platelet count (PLT) \\\u003C100×10⁹\u002FL, hemoglobin (Hb) \\\u003C90 g\u002FL;\n  2. Aspartate aminotransferase (AST) \\>2.5× upper limit of normal (ULN) and\u002For alanine aminotransferase (ALT) \\>2.5×ULN, serum total bilirubin (TBIL) \\>1.5×ULN;\n  3. Creatinine (Cr) \\>1.5×ULN;\n  4. For patients not receiving anticoagulant or antithrombotic therapy: international normalized ratio (INR) \\>1.7 or activated partial thromboplastin time (APTT) \\>1.25×ULN; for patients receiving anticoagulant or antithrombotic therapy: INR \\>3.0 or APTT \\>1.5×ULN.\n* Diagnosis of immunodeficiency disease, or long-term use of immunosuppressants or systemic corticosteroids at high doses within a short period before screening.\n* Epilepsy, Alzheimer's disease, Parkinson's disease, severe depression, or other neurological or psychiatric disorders that, in the investigator's opinion, could affect the participant's ability to participate in the trial or interfere with study assessments.\n* Presence of autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, etc.).\n* Inability to undergo cranial CT\u002FMRI examination for any reason (e.g., metallic implants such as cardiac pacemakers, claustrophobia, etc.).\n* Participation in another clinical trial of an investigational drug within 3 months before screening.\n* Pregnancy, breastfeeding, planned pregnancy, or inability to use effective contraceptive measures.\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for inclusion in this study.","ALL","18 Years",{"count":19,"type":20},35,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Study Methods: The trial consists of two phases, both including a placebo control.\n\nPhase Ia (single-dose, dose-escalation): Three dose groups (low, medium, high) are set. This is a multicenter, randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial. Dose escalation to the next level is permitted only after safety assessment at 28 days post-dose in the previous group.\n\nPhase Ib (multiple-dose): Based on Phase Ia results, two dose groups will be selected. The product is administered on Day 0, Day 7, and Day 14 (3 doses total). The trial remains randomized, double-blind, and placebo-controlled.",[26,27],"Acute Ischemic Stroke","AIS",[27,29],"hUC-MSCs","NOT_YET_RECRUITING","2026-06-01",{"date":33,"type":34},"2026-06-05","ACTUAL",{"date":36,"type":20},"2026-06-30",{"date":38,"type":20},"2029-11-30",{"name":40,"class":41},"BOE Technology Group Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100632967","phase-3-a-multicentre-randomised-double-blind-placebo-parallel-controlled-phase--clinical-trial-evaluating-the-efficacy-and-safety-of-bxos110-injection-in-the-treatment-of-acute-ischaemic-stroke-within-3-hours-of-onset-100632967","NCT07520565","A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.","Inclusion Criteria:\n\n1. Age18\\~85 (including 18 and 85 years)，no gender limitation;\n2. Subjects diagnosed with acute ischaemic stroke according to the Chinese Guidelines for Clinical Management of Cerebrovascular Disease (2nd edition);\n3. 8 ≤ NIHSS score ≤ 25 before randomisation，and the sum of the score of the 5th upper limb and the 6th lower limb was ≥ 2 ;\n4. Within 3h of stroke onset and expected to be able to start receiving the investigational product within 3 h of stroke onset (note: stroke onset time was calculated from the onset time of stroke symptoms; if stroke onset occurs during sleep, the stroke onset time should be taken as the latest normal appearance time);\n5. First stroke onset, or have a history of stroke but good prognosis (mRS score ≤1);\n6. Subjects who are able to understand and comply with the study procedures, and who agree to sign the study informed consent form in writing to indicate that they are willing to participate in the trial (the informed consent form can be signed by subjects or their legal representatives).\n\nExclusion Criteria:\n\n1. Imaging confirmed intracranial hemorrhagic disease (hemorrhagic stroke, epidural hematoma, intracranial hematoma, subarachnoid hemorrhage, ventricular hemorrhage, traumatic cerebral hemorrhage, etc.);\n2. Severe disturbance of consciousness: NIHSS 1a score ≥2 points;\n3. After aggressive antihypertensive therapy, hypertension still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥110 mmHg;\n4. Severe hyperglycemia\u002Fhypoglycemia: blood glucose≥400 mg\u002FdL (22.2 mmol\u002FL), or ≤50 mg\u002FdL (2.8 mmol\u002FL);\n5. Heart rate \\\u003C 50 beats \u002Fmin or heart rate \\> 120 beats \u002Fmin; Heart failure, unstable angina pectoris, acute myocardial infarction, and severe arrhythmias within the previous 6 months;\n6. Previously diagnosed severe hepatic and renal dysfunction and determined by the investigators as affect the subjects;\n7. Patients who have suffered from malignant tumors or are undergoing anti-tumor treatment within the past 5 years;\n8. Patients who have been treated with neuroprotective agents after current stoke onset;\n9. Have a epilepsy history or have epilepsy symptoms after current stoke onset;\n10. Combined with other mental illnesses, resulting in inability or unwillingness to cooperate;\n11. Combined with claudication, osteoarthropathy, etc., resulting in limb movement dysfunction, which is determined by investigators to affect neurological function test;\n12. History of severe head trauma or stroke within 3 months before screening;\n13. History of severe food or drug allergy, or known allergy to the investigational drug and its excipients;\n14. Expected survival period is less than 3 months;\n15. Pregnant, planning pregnancy or breastfeeding patients;\n16. Suspected or confirmed history of alcohol or drug abuse;\n17. Participated in other drug or device clinical trial within the 1 months prior to screening or are participating in a other clinical trial;\n18. Other conditions, and the investigator assessed that participation in the study might increase the patient's risk or that participation in the study was deemed inappropriate by the investigator.","85 Years",{"count":51,"type":20},1112,[53],"PHASE3","The purpose of this study was to evaluate the efficacy of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke",[27],"RECRUITING","2026-04-02",{"date":59,"type":34},"2026-04-09",{"date":61,"type":34},"2026-01-19",{"date":63,"type":20},"2027-12",{"name":65,"class":41},"Biocells (Beijing) Biotech Co.,Ltd",9,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100570085","a-randomized-clinical-trial-on-urgent-angioplasty-for-intracranial-atherosclerotic-stenosis-related-large-vessel-occlusion-after-mechanical-thrombectomy-100570085","NCT06702657","A Randomized Clinical Trial on Urgent Angioplasty for IntraCranial Atherosclerotic Stenosis-related Large-Vessel Occlusion After Mechanical Thrombectomy","A Randomized Clinical Trial on Urgent Angioplasty for IntraCranial Atherosclerotic Stenosis-related Large-Vessel Occlusion After Mechanical Thrombectomy (ICAS LVO-MT)","ICAS LVO-MT","Inclusion Criteria:\n\nClinical inclusion criteria:\n\n1. Age ≥ 18 years\n2. National Institutes of Health Stroke Scale (NIHSS) score ≥6 before randomization\n3. To receive mechanical thrombectomy \\\u003C24 hours after AIS onset according to local guidelines\n4. Signed informed consent form obtained from the subject (or approved surrogate)\n\nImaging inclusion criteria:\n\n1. For subjects with anterior circulation stroke, ASPECTS ≥6 based on CT or DWI\n2. For subjects with posterior circulation stroke, posterior circulation ASPECTS (pc-ASPECTS)≥6 and pons-midbrains index (PMI) \\\u003C 3 based on CT or DWI\n\nAngiography inclusion criteria:\n\n1. The responsible occluded vessel is immediately recanalized (eTICI≥2b) after mechanical thrombectomy, ICAS is highly suspected and the focal residual stenosis of the main trunk is≥70%, and the responsible occluded vessels include the intracranial segment of the internal carotid artery, the M1 segment of the middle cerebral artery, the V4 segment of the vertebral artery, and the basilar artery\n2. According to the judgment of the neurointerventional physician, the responsible artery is suitable for stenting angioplasty\n\nExclusion Criteria:\n\n1. Pre-stroke mRS \\>2\n2. Intracranial hemorrhage confirmed by CT before mechanical thrombectomy and enrolment\n3. Suspected Intracranial hemorrhage after successful recanalization confirmed by 3D-CT\n4. Tandem lesions: stenosis (or occlusion) of the extracranial segment of the internal carotid artery or vertebral artery combined with occlusion of large intracranial vessels, stenosis of intracranial arteries combined with occlusion of vessels distal to the stenosis\n5. More than two severe stenosis of the responsible occluded vessel (internal carotid artery, middle cerebral artery, vertebral artery, and basilar artery)\n6. Potential cardiac sources of emboli such as atrial fibrillation, left ventricular thrombus, heart valve replacement, atrial septal defect, ventricular septal defect, atrial myxoma, etc.\n7. Current use of oral anticoagulants\n8. Major surgery or serious trauma in the previous 2 weeks\n9. Contraindication for mechanical thrombectomy or stenting angioplasty\n10. Contraindication for antiplatelet treatment or allergy to contrast agent\n11. History of gastrointestinal or urinary bleeding in the previous 3 weeks\n12. Life expectancy less than 1 years\n13. Current pregnant or breastfeeding status\n14. Currently participating in another clinical trial that may affect the outcome assessment of this trial\n15. Any other condition that, in the investigator's judgement, deems the individual unsuitable for enrolment.",{"count":76,"type":20},612,[78],"NA","A prospective, multicenter, randomized controlled, open-label, blinded outcome evaluation (PROBE) trial",[27,81,82],"ICAS - Intracranial Atherosclerosis","Stroke",[84,27,85],"ICAS","STROKE","2025-03-14",{"date":88,"type":34},"2025-03-18",{"date":90,"type":20},"2025-03-15",{"date":92,"type":20},"2027-08-15",{"name":94,"class":95},"Changhai Hospital","OTHER",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":103,"sex":104,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":42},"100394922","phase-3-evaluate-the-efficacy-immunogenicity-and-safety-of-9-valent-hpv-recombinant-vaccine-in-chinese-healthy-females-100394922","NCT04422366","Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years","Inclusion Criteria:\n\n(If the \"\\*\" option is not met during screening, the visit can be rescheduled)\n\n* Chinese women aged 20-45 who can provide legal identification and have a sexual life history;\n* The subject fully understands the study procedures, understands the risks and benefits associated with participating in the study, and voluntarily signs the informed consent;\n* Subjects are able to read, understand and fill in application forms such as diary CARDS and contact CARDS, and participate in follow-up according to the study requirements;\n* Subjects have not been screened for cervical cancer, or have been screened for cervical cancer but the results are normal;\n* \\*0 days before the gynecological visit, no sex within 48 hours, no flushing or vaginal cleaning within 72 hours, no use of vaginal drugs or preparations;Subject agrees to refrain from sexual intercourse (including anal, vaginal, or genital\u002Fgenital contact of the same or opposite sex) for 48 hours prior to any visit that includes gynecological sample collection, and to refrain from vaginal flushing, vaginal cleansing, or use of vaginal medications or preparations for 72 hours;\n* When the subjects were enrolled, the urine pregnancy test was negative (sensitivity was 25mIU\u002Fml cox-hcg), they were not in the lactation period and had no family planning within 7 months after enrollment (1 month before whole-course inoculation).2 weeks before included in the study, effective contraceptive measures has been adopted and agreed to in the first seven months after the study (vaccinations after 1 months ago) continue to adopt effective contraceptive measures (effective contraceptive measures include: the pill, injection or embedded contraception, slow-release local birth control pills, hormone patch, the intrauterine device (IUD), sterilization, abstinence, condom (men), diaphragm, cervical cap, etc.), rhythm, withdrawal and emergency contraception is unacceptable contraception;\n* \\*body temperature \\\u003C37.3℃ (underarm body temperature)\n\nExclusion Criteria:\n\nFirst dose exclusion criteria(If the \"\\*\" option is met during screening, the visit can be rescheduled)\n\n* Have been vaccinated with commercially available HPV vaccine in the past or planned to be vaccinated with commercially available HPV vaccine during the study period;Or have participated in a clinical trial of the HPV vaccine and have received a vaccine\u002Fplacebo vaccination;\n* Previous positive history of HPV;\n* Has a history of abnormal cervical cytology, including squamous intraepithelial lesions (SIL) or not clear meaning of the atypical squamous cells (ASC - US), except the atypical squamous cells - not highly squamous intraepithelial lesion (ASC - H), atypical glandular epithelial cells, or those with cervical intraepithelial neoplasia (CIN) and carcinoma in situ or abnormal cervical biopsy results such as the history;\n* Past history of anal and genital diseases (such as vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, genital warts, vulvar cancer, vaginal cancer and anal cancer, etc.);\n* Received total hysterectomy or pelvic radiotherapy;\n* Cervical insufficiency or abnormal cervical structure (judged by the results of routine gynecological examination);\n* Previous sexual history (including syphilis, gonorrhea, chancre, venereal lymphatic granuloma, granuloma inguinal) or have obvious condyloma;\n* A history of seizures, convulsions or convulsions, or a family history of mental illness;\n* Have participated in other gynecology-related clinical trials within 6 months, and have used or plan to use other investigational or unregistered products (drugs or vaccines) other than the vaccine in this study within 3 months;\n* A history of severe allergies requiring medical intervention, such as anaphylactic shock, anaphylactic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis reaction (Arthus reaction), etc.A history of severe adverse reactions to previous vaccinations or a history of severe allergies to any of the components of the vaccine under study (histidine, polysorbate, aluminum phosphate, sodium borate, amorphous aluminum phosphate sulfate adjuvant and water for injection) (such as swelling of the mouth and throat, dyspnea, hypotension or shock, severe urticaria, etc.);\n* Subject receives any immunoglobulin or blood product within 3 months prior to the first dose of vaccination, or plans to receive such product within the next 7 months (1 month prior to the full course of vaccination);\n* Subjects present\u002Fpresent with immune impairment or have been diagnosed with congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases;\n* Immunosuppressant therapy within 1 month before the first dose of vaccination, such as long-term use of systemic glucocorticoid therapy (≥2mg\u002Fkg\u002F day, for more than 2 weeks, such as prednisone or similar drugs;Topical administration (such as ointment, eye drops, inhalant or nasal spray) not exceeding the recommended dosage in the directions or showing any signs of systemic exposure) or planning to receive such treatment within the next 7 months (1 month before the full course of inoculation);\n* Absence of spleen or functional absence of spleen, and absence of spleen or splenectomy in any case;\n* Patients with severe liver, kidney and cardiovascular diseases, diabetes or malignant tumor with complications;\n* Patients with thrombocytopenia or any coagulation disorders that may be contraindications to intramuscular injection;\n* \\* subjects received inactivated or recombinant vaccines within 14 days prior to study enrollment, or attenuated live vaccines within 28 days prior to study enrollment;\n* \\* an acute illness or an acute episode of a chronic illness within 3 days prior to vaccination or the use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.);\n* \\* the first dose of vaccine was in pregnancy at the time of vaccination, or the end of pregnancy had not exceeded 6 weeks;\n* \\* after questioning, subjects had fever symptoms (subaxillary body temperature ≥37.3℃) before the first day of vaccination (within 24 hours before vaccination);\n* \\* the subject is in the menstrual period;\n* \\* severe acute vaginitis and suppurative cervicitis found by naked eye during gynecological examination (purulent secretion visible by naked eye);\n* Blood pressure on physical examination before the first dose of vaccination was higher than normal or increased (systolic blood pressure ≥140mmHg and\u002For diastolic blood pressure ≥90mmHg);\n* Gynecological examination before the first dose of vaccination suspected genital warts, or on the basis of clinical symptoms and signs suspected vulva, vagina or cervical precancerous lesions and the possibility of cancer;\n* Subjects may be unable to comply with the study procedure, comply with the agreement, or plan to permanently relocate from the region prior to completion of the study, or may be permanently absent from the region during the scheduled visit;\n* In the opinion of the investigators, the subjects had any other factors that made them unsuitable to participate in the clinical trial, so that continued participation in the study could not guarantee the maximum benefit of the subjects.\n\nSecond and third doses of vaccine were excluded criteria\n\n* new discoveries or new occurrences that meet the first dose exclusion criteria (except for articles 2, 3, 4, 21);\n* other serious adverse events: the investigator decides whether to terminate the experimental vaccination according to its treatment needs;\n* the investigator assays for any other reasons that may be considered necessary to terminate the trial vaccination.\n\nSecond and third doses of vaccine were delayed criteria\n\nVaccination may be postponed if:\n\n* fever (underarm body temperature ≥37.3℃);\n* before inoculation (on the day of inoculation), the urine pregnancy test was positive (sensitivity was 25mIU\u002Fml n-hcg);\n* acute illness or acute attack of a chronic disease or use of antipyretic, analgesic and antiallergic drugs (e.g., acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) within 3 days before vaccination;\n* insufficient interval between other vaccines (inactivated or recombinant vaccines received within 14 days prior to vaccination, or any live attenuated vaccine received within 28 days);\n* any immunoglobulin or blood products received during vaccination should be administered at least 3 months after the vaccination;\n* other circumstances that can be postponed as judged by the researcher.",true,"FEMALE","20 Years","45 Years",{"count":108,"type":20},8000,[53],"This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years .",[112,113,114,115,116,117,118,119,120,121,122,123,124,27],"Cervical Cancer","Vulvar Cancer","Vaginal Cancer","CIN1","CIN2","CIN3","VaIN1","VaIN2","VaIN3","Genital Wart","VIN 1","VIN 2","VIN 3","2024-06-06",{"date":127,"type":34},"2024-06-07",{"date":129,"type":34},"2020-04-28",{"date":131,"type":20},"2029-09-15",{"name":133,"class":41},"Shanghai Bovax Biotechnology Co., Ltd.",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":42},"100475090","screening-and-intervention-for-ais-in-haikou-hainan-province-china-100475090","NCT05466383","Screening and Intervention for AIS in Haikou, Hainan Province, China","Screening and Intervention for Adolescent Idiopathic Scoliosis in Haikou, Hainan Province, China","Inclusion Criteria:\n\n1. 9 years ≤ age ≤ 16 years\n2. Diagnosis of AIS\n3. 10°≤Cobb's angle\\\u003C45°\n4. Signed informed consent form\n\nExclusion Criteria:\n\n1. With other developmental disorders, musculoskeletal disorders, nerve disorders, infection disorders, mental disorders, and other disorders\n2. Obvious deformity of lower limbs and(or) feet\n3. Previous or ongoing treatment of AIS\n4. Difficulty to read, understanding, and complete the study questionnaires\n5. Any criteria, which, in the opinion of the investigator, suggest that the subject would not be compliant with this study protocol","9 Years","16 Years",{"count":144,"type":20},5000,[78],"This is a single-center, prospective, non-randomized, open-label, interventional, real-world study. The mild\u002Fmoderate AIS patients will be recruited through screening of 250,000 primary and secondary school students in Haikou, Hainan Province. The patients will be treated with different non-surgical interventions (exercise intervention or brace intervention) according to the physician's recommendations and the patient's intention. Patients will be followed up for 36 months to evaluate the effectiveness and safety of non-surgical interventions in the real world.",[27],"2023-08-01",{"date":150,"type":34},"2023-08-04",{"date":152,"type":34},"2022-10-24",{"date":154,"type":20},"2026-12-31",{"name":156,"class":95},"Chaoyin Jiang"]